Media stories about CTI BioPharma Corp. (NASDAQ:CTIC) have been trending somewhat positive on Monday, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CTI BioPharma Corp. earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.5671167522799 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Separately, Jefferies Group LLC began coverage on CTI BioPharma Corp. in a report on Tuesday, September 12th. They set a “buy” rating and a $7.50 price target for the company.

CTI BioPharma Corp. (NASDAQ:CTIC) traded down 3.57% during mid-day trading on Monday, reaching $3.24. The company had a trading volume of 180,610 shares. The company’s 50-day moving average is $3.32 and its 200-day moving average is $3.73. The stock’s market capitalization is $102.79 million. CTI BioPharma Corp. has a one year low of $0.36 and a one year high of $6.48.

CTI BioPharma Corp. (NASDAQ:CTIC) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.63. The company had revenue of $22.23 million during the quarter. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. Equities research analysts anticipate that CTI BioPharma Corp. will post ($1.26) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/25/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-cti-biopharma-corp-ctic-share-price.html.

CTI BioPharma Corp. Company Profile

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Insider Buying and Selling by Quarter for CTI BioPharma Corp. (NASDAQ:CTIC)

Receive News & Stock Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related stocks with our FREE daily email newsletter.